Centre Catherine de Sienne

The trials here

What the 8 trials at this site are about, from their registry records.

Conditions

• Ovarian cancer5 trials
• Prostate cancer3 trials
• Bladder cancer1 trial
• Colorectal cancer1 trial
• Lung cancer1 trial
• Metastatic breast cancer1 trial
• Multiple myeloma1 trial
• Pancreatic cancer1 trial

Phase

• Phase 33 trials
• Phase 21 trial

Status

• Active, not recruiting4 trials
• Completed2 trials
• Recruiting1 trial
• Terminated1 trial

Lead sponsor

• UNICANCER2 trials
• AstraZeneca1 trial
• Centre Francois Baclesse1 trial
• Daiichi Sankyo1 trial
• Institut Bergonié1 trial
• and 2 more

Running trials

• Active, not recruiting

  Evaluation of the Impact of the Update SMM Criteria on the Natural History of SMM to Establish New Recommendations.

  NCT04144387· Intergroupe Francophone du Myelome· Source

• Active, not recruiting

  Living After a Rare Cancer of the Ovary: Chronic Fatigue, Quality of Life and Late Effects of Chemotherapy

  NCT03418844· Centre Francois Baclesse· Source

• Active, not recruiting

  A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer

  NCT01957436· Phase 3· UNICANCER· Source

• Active, not recruiting

  Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

  NCT01874353· Phase 3· AstraZeneca· Source

• Recruiting

  COsegregation of VARiants in Panel of Genes

  NCT01689584· Institut Curie· Source

  Contact: Cyriac BLONZ, MD

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Ovarian cancer1 recruiting
• Pancreatic cancer1 recruiting
• Prostate cancer1 recruiting

Closed trials

• Terminated

  A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)

  NCT03248492· Phase 2· Daiichi Sankyo· Source

• Completed

  Role of Geriatric Intervention in Treatment of Older Patients With Cancer (PREPARE)

  NCT02704832· Institut Bergonié· Source

• Completed

  Letrozole in Preventing Breast Cancer in Postmenopausal Women With a BRCA1 or BRCA2 Mutation

  NCT00673335· Phase 3· UNICANCER· Source